Company Description
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally.
The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications.
In addition, the company offers cervical products comprising Spider cervical plating, Streamline OCT, and CervAlign systems; thoracolumbar products consisting of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; and Silex sacroiliac joint fusion systems.
Further, it provides interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain.
Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 232 |
| CEO | Sean Browne |
Contact Details
Address: 664 Cruiser Lane Belgrade, Montana 59714 United States | |
| Phone | 406 388 0480 |
| Website | xtantmedical.com |
Stock Details
| Ticker Symbol | XTNT |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453593 |
| CUSIP Number | 98420P308 |
| ISIN Number | US98420P3082 |
| Employer ID | 20-5313323 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Sean E. Browne | President, Chief Executive Officer and Director |
| Scott C. Neils | Chief Financial Officer |
| Mark A. Schallenberger | Chief Operations Officer |
| Catherine Lundy | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 3, 2025 | 8-K | Current Report |
| Nov 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 10, 2025 | 10-Q | Quarterly Report |
| Nov 10, 2025 | 8-K | Current Report |
| Sep 15, 2025 | ARS | Filing |
| Sep 15, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 15, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |